Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Friday, September 17, 2010

Investorideas.com - Biotech/Pharma Stocks: OTCVolumeleaders.com Reports on Actively Trading OTC Stocks ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: AVXL), (OTCBB: IBPM), (OTCBB: FNCB)

Investorideas.com - Biotech/Pharma Stocks: OTCVolumeleaders.com Reports on Actively Trading OTC Stocks ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: AVXL), (OTCBB: IBPM), (OTCBB: FNCB)



Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial

Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) September 17, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Anavex Life Sciences Corp. (OTCBB: AVXL), IBIOPHARMA, INC. (OTCBB: IBPM), and First National Community Bancorp Inc. (OTCBB: FNCB).

Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders


OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Anavex Life Sciences Corp. (OTCBB: AVXL): "Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.


ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic and neuroprotective properties."

Market Snapshot: (at time of release)
Dow 10,614.25 +19.42 +0.18%
Nasdaq 2,317.07 +13.82 +0.60%
S&P 500 1,127.04 +2.38 +0.21%
10 Yr Bond(%) 2.7520% -0.0700
Oil 73.66 -0.91 -1.22%
Gold 1,275.60 +3.70 +0.29%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

No comments:

Post a Comment